| Previous Close | 0.2900 |
| Open | 0.2750 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 0.0600 - 0.2750 |
| 52 Week Range | 0.0300 - 0.5100 |
| Volume | 96,545 |
| Avg. Volume | 8,412 |
| Market Cap | 1.647M |
| Beta (3Y Monthly) | -1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NIAGARA FALLS, N.Y., Oct. 2, 2018 /PRNewswire/ -- Positron Corporation (POSC)(the "Company"), a nuclear medicine healthcare company, is pleased to announce the sale of its Attrius PET scanner to a prominent cardiology practice in the US as they expand their services to include cardiac PET imaging. Positron's President, Adel Abdullah stated, "Its sale is significant as representation of the growing demand for cardiac PET and further proof of the value proposition Positron offers in meeting such demand. "We see demand for PET imaging continuing to accelerate further increasing the need for radiopharmaceuticals and imaging technology. We believe that Positron's Attrius PET scanner, clinical services and ability to provide innovative business structures is a perfect solution for all groups seeking to add cardiac PET to their practice.
NIAGARA FALLS, N.Y., Sept. 27, 2018 /PRNewswire/ -- Positron Corporation (POSC)(the "Company"), a nuclear medicine healthcare company, announces the appointment of Adel Abdullah as its President. Mr. Abdullah will also serve as a Director of the Board. Mr. Abdullah will lead the Company in its strategic plan and long term objectives moving forward. Adel Abdullah has been instrumental to Positron's ability to deliver world class PET imaging technology, clinical & technical services to customers for over 10 years and will continue to do so for Positron's customers.